This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub



EfficacyEfficacyKey HighlightsEfficacyHospitalisation DataSafetySafetySafetyAdverse Event Management: VOD/SOSKey PrecautionsDosingDosingDosingAdministrationSupport and ResourcesSupport and ResourcesSupport and ResourcesGuidelinesFast FactsPharmacy GuidePatient SupportDevelopments in Leukaemia Care videoKey data from the INO-VATE study videoManagement of Refractory/Relapsed ALL videoMRD PubExplainer videoINO-VATE PubExplainer videoVideosMaterials

The content of this website has been produced in line with the BESPONSA® (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA Prescribing Information for Great Britain click here. BESPONSA Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Key HighlightsCompared with standard chemotherapy, BESPONSA offers in R/R ALL:With BESPONSA, bridge more of your R/R ALL patients to curative therapy than with standard chemotherapy1

​​​​​​​*Data for CR/CRi from the prespecified primary analysis of n = 109 in either arm. Between-group differences were 51.4% (97.5% CI, 38.4–64.3) for CR/CRi and 50.3% (97.5% CI, 29.9–70.6) for CR/CRi (MRD negative); p < 0.001.
​​​​​​​The two-sided p values for between-group differences were determined by means of the chi-square test or Fisher’s exact test (if any cell count was < 5).
†Data for transplant and OS analysis from the ITT population: 2-year OS 22.8% vs 10.0% with standard chemotherapy.2 ‡HR, 0.751 (97.5% CI, 0.588–0.959; 2-sided p-value = 0.0210).
Additional OS data are available in the current BESPONSA SmPC.2 A modified analysis of median OS data, carried out by the European Medicines Agency, demonstrated a significantly longer median OS with BESPONSA compared with standard chemotherapy.5

CI, confidence interval; CR, complete remission; CRi, complete remission with incomplete haematological recovery of peripheral blood counts; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; ITT, intention-to-treat; MRD, minimal residual disease; OS, overall survival; QoL, quality of life; R/R ALL, relapsed/refractory acute lymphoblastic leukaemia; SC, standard chemotherapy; SmPC, Summary of Product Characteristics.​​​​​​​

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn moreLoading
Key data from the INO-VATE study 

Here Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn moreLoading

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

ReferencesKantarjian HM, et al. N Engl J Med 2016;375:740–753BESPONSA Summary of Product Characteristics for Great Britain click here. BESPONSA Summary of Product Characteristics for Northern Ireland click here.Marks DI, et al. Cancer Med 2019; 5959-5968Kantarjian HM, et al. Cancer 2018; 124; 2151-2160European Medicines Agency. EPAR, inotuzumab (EMA/289046/2017). Available at: [accessed August 2021]
PP-INO-GBR-0496. August 2021
Quick links Access Support and Resources to read the guidelines, watch videos with leading specialists.  Access  here Loading

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021